Skip to main content
Equibles
ELTX logo

ELTX · Elicio Therapeutics, Inc. · Metrics

Track ELTX — free

Use ELTX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ELTX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.05 -0.06 (-2.84%) At close · Sep 11
Russell 2000 member Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“We are currently facing substantial doubt about our ability to continue as a going concern, given our cash position and cash runway.”
View the 10-Q filed Aug 13, 2026
Market Cap
$53.88M
Shares
26.28M

ELTX metrics

58 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$2.05
Market cap
$53.88M

Price action

20 metrics
Price change (1W)
-14.9%
Price change (30D)
-33.7%
Price change (3M)
-86.2%
Price change (6M)
-83.2%
Price change (YTD)
-74.2%
Price change (1Y)
-82.3%
Trailing year
Price change (5Y)
—
52-week high
$14.85
52-week low
$2.05
Change from 52-week high
-86.2%
Change from 52-week low
+0.0%
Annualized volatility
141.6%
Annualized volatility (3M)
250.4%
Beta
0.2
RSI (14D)
21.3
Price vs SMA 50
-30.8%
Price vs SMA 200
-74.0%
Avg volume (3M)
1.74M
Relative volume
0.3
Average dollar volume
$7.12M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
26.28M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
82.5×
reciprocal yield 1.2%
P / book
6.8
reciprocal yield 14.7%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-70.2%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-06-15

Profitability

9 metrics
Gross margin
100.0%
Operating margin
-1,031.4%
Trailing 12 months
Net margin
-1,225.9%
Gross profit (TTM)
—
Operating profit (TTM)
−$37.92M
Net income (TTM)
−$37.84M
Trailing 12 months
Diluted EPS (TTM)
$-2.13
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.09

Growth

11 metrics
Revenue growth YoY
-100.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$653,000
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+19.8%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-476.8%
Return on assets
-120.8%
Debt / equity
1.2
Current ratio
2.8
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
2.8
Interest coverage
-24.0
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$13.95M
Latest balance sheet
Cash & equivalents
$23.48M
Total assets
$31.33M
Total debt
$9.54M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$37.69M
Capital expenditures (TTM)
—
R&D (TTM)
$23.69M
SG&A (TTM)
—
Stock compensation (TTM)
$3.27M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
55
13F filer change QoQ
+6
Institutional ownership
22.1%

Short interest

3 metrics
Short interest
6.0%
Latest settlement · 5.3 days to cover
Days to cover
5.3d
Short-squeeze score
61 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1601485 CUSIP 28657F103 13F (30d) 19 filings 19 filers Visit website Investor relations